Letter |

Malaysia’s compulsory licence for sofosbuvir is a positive step for public health and innovation

Photograph by Todd Brown

Médecins Sans Frontières (MSF) Access Campaign wrote a letter of support to the Malaysian government commending the issuance of a government use licence to enable access to an affordable version of hepatitis C drug sofosbuvir. The licence issued by Malaysia on 20 September 2017 eliminated patent barriers and has resulted in the scale-up of treatment in public hospitals throughout the country. 

In the letter, the Access Campaign urged the Malaysian government to continue to reject any pressure from pharmaceutical corporations or their political allies to reverse the government use licence.